UniversitÄt Autonoma De Barcelona

Consejo Superior De Investigaciones Cientificas

Universidad De Barcelona

Mercedes Unzeta López

José Luis Marco Contelles

Abdelouahid Samadi

Francisco Javier Luque Garriga

Joan Montaner Vilallonga

Irene Bolea Tomás

Mar Hernández-Guillamón

The present invention relates to a compound of formula (I):  wherein: Rand Rare selected from among H and C1-C10 alkyl; Ris selected from among H, &#x2014;OR, N, &#x2014;CN, &#x2014;C(O)R, &#x2014;C(O)OR, &#x2014;C(O)NRR, &#x2014;C&#x2550;NR, &#x2014;OC(O)R, &#x2014;NRR, &#x2014;NRC(O)R, &#x2014;NO, &#x2014;N&#x2550;CRR, halogen and C1-C10 alkyl, wherein Rand Rare selected from among H, alkyl, alkenyl, cycloalkyl and aryl; X, Y, Z, Zand Zare selected independently from among CH and N; A is selected from among (CH), NH, O and CO, wherein n is an integer between 1 and 6, to the procedure for the obtainment of said compounds, to a pharmaceutical composition comprising said compound, and to the use thereof in the treatment of a neurodegenerative disease, more particularly treatment of Alzheimer's or Parkinson's disease.

Derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases

The invention provides a method for predicting a hemorrhagic disorder in a patient consisting determining amine oxidase and, particularly, VAP-1 in a sample from said patient. The invention also provides pharmaceutical compositions comprising an inhibitor of amine oxidase and an antithrombotic agent as well as the use of an inhibitor of amine oxidase for treatment of hemorrhagic disorders.

Methods and compositions for the treatment and diagnosis of haemorrhagic conversion

Growing community of inventors

Barcelona, Spain

Mercedes Unzeta López